Anaphylm (dibutepinephrine)

Epinephrine is recommended as first-line treatment for anaphylaxis in every major guideline, but delivery of that treatment fails at several points. Community administration is uncommon: one review reports that 21% of children and 7% of adults experiencing anaphylaxis in community settings receive epinephrine before hospital arrival, and the same review describes underuse in up to 64% of pre-hospital events. Delay is consequential, because delayed administration of more than 60 minutes from onset is an independent predictor of biphasic recurrence, and in fatality case series most people who died of anaphylaxis did not receive timely epinephrine. Failure to carry a device contributes: the 2023 practice parameter update reports suboptimal rates of auto-injector prescription fills and refills, carriage, and use, and a 2025 review reports auto-injector use rates of 16% to 32% even among people who have been prescribed one, with device design, fear of needles, injection-site pain, social embarrassment, and concern about accidental needle injuries named as barriers. The World Allergy Organization guidance adds that limited availability of auto-injectors, and their affordability for some patients, remains a problem in many countries, and that needle phobia is listed among the considerations against managing an episode at home.

Device-related problems add to the gap. Reported auto-injector injuries include lacerations and embedded needles when a person moves during administration, when the device discharges off center, or when the needle bends after striking bone. Needle length is a design constraint in infants with low body mass, in women, and in adults with a body mass index above 25, and ultrasound-based work indicates that the risk of subcutaneous rather than intramuscular delivery is highest in women with obesity. Cost is a further constraint: a 2018 survey found that 97% of parents of children with food allergy in the United States felt financially burdened by the cost of auto-injectors, and the average wholesale price of two EpiPens rose from $113.27 in 2007 to $730.33 in 2016, with United States packaging sold only in two-unit packs. Storage adds a practical limit, since auto-injectors are labeled for 20°C to 25°C with excursions permitted only to 15°C to 30°C and must be protected from light, and the approved nasal spray does not deliver epinephrine while frozen. For intranasal epinephrine, the evidence base rests on pharmacokinetic and pharmacodynamic comparisons rather than on randomized efficacy trials in anaphylaxis, because ethical and practical constraints make such trials difficult; the label also states that subjects with structural or anatomical nasal conditions were not studied and advises considering another route for those patients. The 2023 practice parameter update states explicitly that it addresses only injectable epinephrine and that noninjectable routes had no clinical evidence base at the time it was written.